Patents by Inventor Alex R. Zelenchuk

Alex R. Zelenchuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140127137
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: June 17, 2013
    Publication date: May 8, 2014
    Applicant: Cercacor Laboratories, Inc
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Patent number: 8466286
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: June 18, 2013
    Assignee: Cercacor Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Patent number: 8311607
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: November 13, 2012
    Assignee: Luma Imaging Corporation
    Inventor: Alex R. Zelenchuk
  • Publication number: 20120052018
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: August 22, 2011
    Publication date: March 1, 2012
    Applicant: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Publication number: 20120046554
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Application
    Filed: August 22, 2011
    Publication date: February 23, 2012
    Applicant: LUMA IMAGING CORPORATION
    Inventor: Alex R. Zelenchuk
  • Patent number: 8029765
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 4, 2011
    Assignee: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Patent number: 8008088
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: August 30, 2011
    Assignee: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Patent number: 8005527
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: August 23, 2011
    Assignee: Luma Imaging Corporation
    Inventor: Alex R. Zelenchuk
  • Patent number: 7831298
    Abstract: Systems, apparatus and techniques for non-invasive optical probing of various substances, and systems, apparatus and techniques for detecting, diagnosing and treating a disease in lungs and other organs using the non-invasive optical probing, including mapping physiological functions of tissues in lungs and other organs.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: November 9, 2010
    Assignee: Tomophase Corporation
    Inventors: Feiling Wang, Alex R. Zelenchuk, Xiao-Li Li
  • Publication number: 20090004108
    Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.
    Type: Application
    Filed: December 23, 2004
    Publication date: January 1, 2009
    Applicant: Masimo Laboratories, Inc.
    Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
  • Patent number: 7310547
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Grant
    Filed: July 19, 2004
    Date of Patent: December 18, 2007
    Assignee: Medispectra, Inc.
    Inventor: Alex R. Zelenchuk
  • Patent number: 7225005
    Abstract: A system and method for determining an in vivo property of a tissue or blood is described. The in vivo property may be a hematocrit value, a hemoglobin concentration, or a combination thereof. The system can automatically determine a location of a subcutaneous blood vessel. Based on the automatically determined location, the system illuminates the blood vessel with a light beam and detects light resulting from the illumination. The system determines the in vivo property based on the detected light. Alternatively, or in combination, the system displays an image corresponding to a spatial relationship between a subcutaneous blood vessel and a light beam. Based on the image, an operator can adjust the light beam with respect to the blood vessel to have a selected spatial relationship. The system determines an in vivo property based on the illumination of the blood vessel when the light beam has the selected spatial relationship.
    Type: Grant
    Filed: December 14, 2004
    Date of Patent: May 29, 2007
    Assignee: Intelligent Medical Devices, Inc.
    Inventors: Howard B. Kaufman, Alex R. Zelenchuk
  • Patent number: 7103401
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, about 403 nm, about 414 nm, and about 431 nm. The intensities of the 403 nm and 414 mn radiation are normalized using the 431 nm intensity. A score is determined using the ratios in a linear discriminant analysis (LDA). The tissue under examination is resected or not, based on the outcome of the LDA.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: September 5, 2006
    Assignee: MediSpectra, Inc.
    Inventors: Kevin T. Schomacker, Norman S. Nishioka, Alex R. Zelenchuk
  • Patent number: 6768918
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: July 27, 2004
    Assignee: MediSpectra, Inc.
    Inventor: Alex R. Zelenchuk
  • Publication number: 20040010195
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, one of which corresponds to an isosbestic point. In one example, the isosbestic point occurs at about 431 nm. The intensities of the observed signals are normalized using the 431 nm intensity. A score is determined using the ratios in a discriminant analysis. The tissue under examination is resected or not, based on the diagnosis of disease or health, according to the outcome of the discriminant analysis.
    Type: Application
    Filed: July 10, 2002
    Publication date: January 15, 2004
    Inventor: Alex R. Zelenchuk
  • Publication number: 20040010187
    Abstract: A system and method for the in situ discrimination of healthy and diseased tissue. A fiberoptic based probe is employed to direct ultraviolet illumination onto a tissue specimen and to collect the fluorescent response radiation. The response radiation is observed at three selected wavelengths, about 403 nm, about 414 nm, and about 431 nm. The intensities of the 403 nm and 414 mn radiation are normalized using the 431 nm intensity. A score is determined using the ratios in a linear discriminant analysis (LDA). The tissue under examination is resected or not, based on the outcome of the LDA.
    Type: Application
    Filed: July 10, 2002
    Publication date: January 15, 2004
    Inventors: Kevin T. Schomacker, Norman S. Nishioka, Alex R. Zelenchuk